Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hyperlipoproteinemias

  Free Subscription


Articles published in Curr Opin Lipidol

Retrieve available abstracts of 35 articles:
HTML format
Text format



Single Articles


    April 2017
  1. ROTONDO D, Davidson J
    Gene therapy, a promising treatment for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2017;28:216-217.
    PubMed     Text format    


    March 2017
  2. CALANDRA S, Tarugi P, Bertolini S
    Impact of rare variants in autosomal dominant hypercholesterolemia causing genes.
    Curr Opin Lipidol. 2017 Mar 18. doi: 10.1097/MOL.0000000000000414.
    PubMed     Text format     Abstract available


    February 2017
  3. KINDT I, Mata P, Knowles JW
    The role of registries and genetic databases in familial hypercholesterolemia.
    Curr Opin Lipidol. 2017 Feb 6. doi: 10.1097/MOL.0000000000000398.
    PubMed     Text format     Abstract available


  4. BOURBON M, Alves AC, Sijbrands EJ
    Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia.
    Curr Opin Lipidol. 2017 Feb 6. doi: 10.1097/MOL.0000000000000404.
    PubMed     Text format     Abstract available


  5. HOPKINS PN, Lane SR
    Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns.
    Curr Opin Lipidol. 2017 Feb 2. doi: 10.1097/MOL.0000000000000397.
    PubMed     Text format     Abstract available


    January 2017
  6. SANTOS RD
    Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?
    Curr Opin Lipidol. 2017 Jan 5. doi: 10.1097/MOL.0000000000000391.
    PubMed     Text format     Abstract available


    December 2016
  7. HOPKINS PN
    Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening.
    Curr Opin Lipidol. 2016 Dec 24. doi: 10.1097/MOL.0000000000000388.
    PubMed     Text format     Abstract available


  8. KOCKX M, Kritharides L
    Hyperlipidaemia in immunosuppression.
    Curr Opin Lipidol. 2016;27:631-632.
    PubMed     Text format    


  9. NORMAN R, Watts GF, Weintraub W, Gidding SS, et al
    Challenges in the health economics of familial hypercholesterolemia.
    Curr Opin Lipidol. 2016;27:563-569.
    PubMed     Text format     Abstract available


    August 2016
  10. HARALAMBOS K, Ashfield-Watt P, McDowell IF
    Diagnostic scoring for familial hypercholesterolaemia in practice.
    Curr Opin Lipidol. 2016;27:367-374.
    PubMed     Text format     Abstract available


    April 2016
  11. GENCER B, Nanchen D
    Identifying familial hypercholesterolemia in acute coronary syndrome.
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available


  12. BOGSRUD MP, Ulven SM, Holven KB
    Does intrauterine exposure to hypercholesterolemia adversely affect familial hypercholesterolemia phenotype?
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available


  13. MUNDAL L, Retterstol K
    A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries.
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available


  14. HIGGINS CA, Rees A
    Do the mechanisms by which LDL-c levels are reduced influence the extent of clinical benefit which subsequently accrues?
    Curr Opin Lipidol. 2016;27:207-8.
    PubMed     Text format    


  15. STENDER S, Tybjaerg-Hansen A
    Using human genetics to predict the effects and side-effects of drugs.
    Curr Opin Lipidol. 2016;27:105-11.
    PubMed     Text format     Abstract available


    December 2015
  16. BRAHM AJ, Hegele RA
    Combined hyperlipidemia: familial but not (usually) monogenic.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available


  17. SIJBRANDS EJ, Nieman K, Budoff MJ
    Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials.
    Curr Opin Lipidol. 2015;26:586-92.
    PubMed     Text format     Abstract available


  18. GRYN SE, Hegele RA
    Novel therapeutics in hypertriglyceridemia.
    Curr Opin Lipidol. 2015;26:484-91.
    PubMed     Text format     Abstract available


  19. WIERZBICKI AS, Watts GF
    The hinterland of familial hypercholesterolaemia: what do we not know?
    Curr Opin Lipidol. 2015;26:475-83.
    PubMed     Text format     Abstract available


    October 2015
  20. BURKHARDT R
    Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'.
    Curr Opin Lipidol. 2015;26:468-9.
    PubMed     Text format    


    June 2015
  21. RYAN A, Byrne CD
    Importance of early recognition of heterozygous familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available


  22. SJOUKE B, Hovingh GK, Kastelein JJ, Stefanutti C, et al
    Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives.
    Curr Opin Lipidol. 2015;26:200-9.
    PubMed     Text format     Abstract available


  23. BRAAMSKAMP MJ, Hutten BA, Wiegman A
    Early initiation of statin treatment in children with familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015;26:236-9.
    PubMed     Text format     Abstract available


  24. REINER Z
    A comparison of European and US guidelines for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015;26:215-20.
    PubMed     Text format     Abstract available


  25. YEANG C, Witztum JL, Tsimikas S
    'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering.
    Curr Opin Lipidol. 2015;26:169-78.
    PubMed     Text format     Abstract available


  26. TAYLOR BA, Thompson PD
    Muscle-related side-effects of statins: from mechanisms to evidence-based solutions.
    Curr Opin Lipidol. 2015;26:221-7.
    PubMed     Text format     Abstract available


  27. QURESHI N, Minhas R, Wierzbicki AS
    Prioritizing health outcomes in a limited world: writing lipid guidelines.
    Curr Opin Lipidol. 2015;26:188-94.
    PubMed     Text format     Abstract available


  28. ROBINSON JG
    Statins and diabetes risk: how real is it and what are the mechanisms?
    Curr Opin Lipidol. 2015;26:228-35.
    PubMed     Text format     Abstract available


  29. CHRISTOFFERSEN M, Tybjaerg-Hansen A
    Novel genes in LDL metabolism--a comprehensive overview.
    Curr Opin Lipidol. 2015;26:179-87.
    PubMed     Text format     Abstract available


  30. WATERS DD
    LDL-cholesterol lowering and renal outcomes.
    Curr Opin Lipidol. 2015;26:195-9.
    PubMed     Text format     Abstract available


    April 2015
  31. PEARS R, Griffin M, Futema M, Humphries SE, et al
    Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available


  32. SJOUKE B, Hovingh KG, Kastelein JJ, Stefanutti C, et al
    Homozygous autosomal dominant hypercholesterolemia: prevalence, diagnosis, and current and future treatment perspectives.
    Curr Opin Lipidol. 2015.
    PubMed     Text format     Abstract available


  33. LU H, Daugherty A
    Atherosclerosis: cell biology and lipoproteins.
    Curr Opin Lipidol. 2015;26:152-3.
    PubMed     Text format    


    February 2015
  34. SACKS FM
    The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia.
    Curr Opin Lipidol. 2015;26:56-63.
    PubMed     Text format     Abstract available


    June 2014
  35. PATEL SB
    Recent advances in understanding the STSL locus and ABCG5/ABCG8 biology.
    Curr Opin Lipidol. 2014;25:169-75.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: